Tolvaptan treatment for patients with decompensated cirrhosis and advanced hepatocellular carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1872-034x|45|10|E161-E162

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.45, Iss.10, 2015-10, pp. : E161-E162

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma with Decompensated Cirrhosis

By  

Oncology, Vol. 81, Iss. 1, 2011-09 ,pp. : 39-44

Karger

Access to resources Recommend Favorite

Feasibility of Gemcitabine plus Oxaliplatin in Advanced Hepatocellular Carcinoma Patients with Child-Pugh B Cirrhosis

By  

Oncology, Vol. 84, Iss. 1, 2012-10 ,pp. : 32-38

Karger

Access to resources Recommend Favorite

Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 85-92

Karger

Access to resources Recommend Favorite

Treatment of Hepatocellular Carcinoma with Child-Pugh C Cirrhosis

By  

Oncology, Vol. 87, Iss. 1, 2014-11 ,pp. : 99-103

Karger

Access to resources Recommend Favorite

Therapeutic effects of short‐ and intermediate‐term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 11, 2015-11 ,pp. : 1062-1070

John Wiley & Sons Inc

Access to resources Recommend Favorite